• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13D/A filed by Rafael Holdings Inc.

    6/9/25 5:22:02 PM ET
    $RFL
    Real Estate
    Finance
    Get the next $RFL alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13D

    Under the Securities Exchange Act of 1934

    (Amendment No. 5)


    Rafael Holdings, Inc.

    (Name of Issuer)


    Class B Common Stock, par value $0.01 per share

    (Title of Class of Securities)


    75062E106

    (CUSIP Number)


    Howard Jonas
    520 Broad Street,
    Newark, NJ, 07102
    (973) 438-1000

    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)
    06/05/2025

    (Date of Event Which Requires Filing of This Statement)


    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. Checkbox not checked

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).






    SCHEDULE 13D

    CUSIP No.
    75062E106


    1 Name of reporting person

    Howard S. Jonas
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    OO
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    1,727,429.00
    8Shared Voting Power

    12,961,565.00
    9Sole Dispositive Power

    1,727,429.00
    10Shared Dispositive Power

    12,961,565.00
    11Aggregate amount beneficially owned by each reporting person

    14,688,994.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    28.4 %
    14Type of Reporting Person (See Instructions)

    IN



    SCHEDULE 13D

    Item 1.Security and Issuer
    (a)Title of Class of Securities:

    Class B Common Stock, par value $0.01 per share
    (b)Name of Issuer:

    Rafael Holdings, Inc.
    (c)Address of Issuer's Principal Executive Offices:

    520 Broad Street, Newark, NEW JERSEY , 07102.
    Item 1 Comment:
    This Amendment No. 5 to Schedule 13D (this "Amendment") supplements and amends the information contained in the Schedule 13D originally filed with the Securities and Exchange Commission (the "Commission") on April 12, 2018, as previously amended by Amendment No. 1, thereto filed with the Commission on February 27, 2023, Amendment No. 2, thereto filed with the Commission on August 3, 2023, Amendment No. 3, thereto filed with the Commission on June 18, 2024, and Amendment No. 4, thereto filed with the Commission on September 30, 2024 (as so amended, the "Schedule 13D"). Terms used but not defined herein shall have the meanings ascribed thereto in the Schedule 13D. This Amendment No. 5 amends Items 3, 4 and 5, as set forth below.
    Item 3.Source and Amount of Funds or Other Consideration
     
    The matters set forth in Item 4 of this Amendment are incorporated in this Item 3 by reference as if fully set forth herein.
    Item 4.Purpose of Transaction
     
    Item 4 is hereby amended and supplemented as follows: On March 25, 2025, Rafael Holdings, Inc. ("Rafael") completed a business combination transaction with Cyclo Therapeutics, Inc. (the "Merger"). In connection with the Merger, Rafael issued approximately 7,132,228 shares of Class B Common Stock. On June 26 2024, 565,538 shares of Class B Common Stock were transferred from Deborah Jonas, the wife of Mr. Jonas, to the Debbie Y. Jonas 2018 Marital Trust. Mr. Jonas maintains shared voting and investment control over the shares held by the Debbie Y. Jonas 2018 Marital Trust. On July 24 2024, 565,538 shares of Class B Common Stock were transferred from the Debbie Y. Jonas 2018 Marital Trust to the Debbie Y. Jonas 2018 Dynasty Trust. Mr. Jonas maintains shared voting and investment control over the shares held by the Debbie Y. Jonas 2018 Dynasty Trust. On June 5, 2025, pursuant to a Standby Purchase Agreement, entered into on May 6, 2025 between Rafael and Mr. Jonas, in connection with a rights offering by Rafael announced on April 29, 2025, certain affiliates, and parties that may be deemed to be affiliates, of Mr. Jonas purchased an aggregate of 16,400,770 shares of Class B Common Stock. Mr. Jonas has beneficial ownership over 13,080,457 of those shares of Class B Common Stock, as follows: (i) the HSJ 2019 Remainder Trust purchased 12,299,207 shares; (ii) Genie A Partners, L.P. purchased 457,031 shares; and (iii) IDT A Partners, L.P. purchased 324,219 shares. Under the rights offering, Rafael stockholders received one subscription right (representing the right to purchase 0.526 of a share of Class B Common Stock at $1.28 per share) for each share of Class A Common Stock or Class B Common Stock held of record as of May 9, 2025. The rights offering provided for a total offering amount of $25.0 million. Mr. Jonas committed to purchasing any unsubscribed shares in a private placement at the same price. Through his role as manager of the general partner of each of Genie A Partners, L.P. and IDT A Partners, L.P., Howard Jonas has sole voting and dispositive power over the shares of Class B Common Stock held by Genie A Partners, L.P. and IDT A Partners, L.P.
    Item 5.Interest in Securities of the Issuer
    (a)
    Items 5 is hereby amended by deleting it in its entirety and substituting the following therefor: As of the date hereof, Mr. Jonas beneficially owns 14,688,994 shares of the Company's Class B Common Stock consisting of: (i) 787,163 shares of Class A Common Stock (which are included herein because they are convertible into the Company's Class B common stock on a one-for-one basis) held by Rafael A Partners, L.P.; (ii) 12,299,207 shares of Class B Common Stock held by the HSJ 2019 Remainder Trust; (iii) 457,031 shares of Class B Common Stock held by Genie A Partners, L.P.; (iii) 324,219 shares of Class B Common Stock held by IDT A Partners, L.P.; (iv) 563,538 shares of Class B Common Stock held by the Debbie Y. Jonas 2018 Dynasty Trust; (v) 159,016 restricted shares of Class B Common Stock held by Mr. Jonas directly, of which 119,262 shares are not subject to contractual restrictions, and 39,754 unvested restricted shares are scheduled to vest on June 13, 2025; and (vi) 98,820 shares of Class B Common Stock held by The Jonas Foundation. Mr. Jonas' beneficial ownership represents approximately 29.2% of the issued and outstanding shares and 50.9% of the combined voting power of the Company's outstanding capital stock (assuming conversion of all shares of Class A Common Stock into shares of Class B Common Stock), based on 787,163 shares of Class A Common Stock and 50,879,164 shares of Class B Common Stock issued and outstanding as of June 9, 2025 (including shares issued pursuant to the Standby Purchase Agreement).
    (b)
    This filing relates to shares that are owned directly by the Reporting Person, shares that are beneficially owned by the Reporting Person, and shares that are owned by trusts and other entities that are for the benefit of the Reporting Person's children or where the Reporting Person and such children hold the pecuniary interests in the shares. In certain instances, Howard Jonas may be in a position to influence voting or dispositive decisions notwithstanding his having no legal or formal voting or dispositive control over the shares. This filing identifies Howard S. Jonas as having joint control, including the power to cast or direct the casting of one-tenth of a vote per share, as well as to dispose or direct the disposition of such shares, over the following shares: (i) 12,299,207 shares of Class B Common Stock held by the HSJ 2019 Remainder Trust, of which Peak Trust Company - NV serves as trustee; (ii) 563,538 shares of Class B Common Stock held by the Debbie Y. Jonas 2018 Dynasty Trust, of which Shmuel Jonas and Peak Trust Company - NV serve as co-trustees; and (iii) 98,820 shares of Class B Common Stock held by The Jonas Foundation, of which Mr. Jonas and his wife, Deborah Jonas, serve as co-trustees. As used herein, the term "beneficially owns" shall be construed as defined by Rule 13d-3 promulgated under the Securities Exchange Act of 1934.
    (c)
    Except as described herein, no transactions in the Class B Common Stock were effectuated by the Reporting Person during the 60 days prior to the date of this Amendment.
    (d)
    Not applicable.
    (e)
    Not applicable.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Howard S. Jonas
     
    Signature:/s/ Joyce J. Mason
    Name/Title:Joyce J. Mason/Attorney in Fact
    Date:06/09/2025
    Get the next $RFL alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $RFL

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $RFL
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Rafael Holdings Reports Third Quarter Fiscal 2025 Financial Results

      NEWARK, N.J., June 11, 2025 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE:RFL, NYSE:RFL), today reported its financial results for the third quarter and first nine months of fiscal year 2025 ended April 30, 2025. "We are pleased to have completed our merger with Cyclo Therapeutics and look forward to reporting the topline data from the 48-week interim analysis of the pivotal Phase 3 TransportNPC™ study evaluating Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C1 anticipated later this month," said Howard Jonas, Chief Executive Officer, Executive Chairman and Chairman of the Board of Rafael Holdings. Mr. Jonas added, "We have enhanced our financial position with the cl

      6/11/25 7:00:00 AM ET
      $RFL
      Real Estate
      Finance
    • Rafael Holdings, Inc. Announces Final Results and Closing of Rights Offering

      NEWARK, N.J., June 04, 2025 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE:RFL, NYSE:RFL) announced today the final results and closing of its $25.0 million rights offering (the "Rights Offering"). The subscription period of the Rights Offering expired at 5:00 P.M. Eastern Time, on May 29, 2025. The Rights Offering resulted in subscriptions for 3,130,480 shares of Class B common stock at an exercise price of $1.28 per share for aggregate gross proceeds of $4,007,014.40.The subscriptions do not reflect subscription rights held by Howard Jonas, Chief Executive Officer, President and Executive Chairman of the Company and Chairman of the Board of Directors of the Company, and his affiliates w

      6/4/25 4:01:00 PM ET
      $RFL
      Real Estate
      Finance
    • Rafael Holdings, Inc. Provides Update to the Description of Subscription Rights Related to its Public Warrants in Connection With its Previously Announced $25 Million Rights Offering to Support Its Commitment to the Development and Potential Launch of Trappsol® Cyclo™

      NEWARK, N.J., May 20, 2025 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE:RFL, NYSE:RFL) today provided an update to the subscription rights related to its Public Warrants in connection with its previously announced rights offering. Under the rights offering, Rafael Holdings has distributed one (1) non-transferable subscription right for each share of Class B common stock or Class A common stock, or for each share of Class B common stock issuable upon exercise of the outstanding warrants, initially issued on May 11, 2020 by Cyclo Therapeutics, Inc. (the "Public Warrants"), in each case, held as of May 9, 2025, the record date for the rights offering. Each subscription right will entitle

      5/20/25 4:01:00 PM ET
      $RFL
      Real Estate
      Finance

    $RFL
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Exec Chairman, CEO & President Jonas Howard S bought $16,742,985 worth of Class B Common Stock (13,080,457 units at $1.28) (SEC Form 4)

      4 - Rafael Holdings, Inc. (0001713863) (Issuer)

      6/9/25 5:19:19 PM ET
      $RFL
      Real Estate
      Finance

    $RFL
    Leadership Updates

    Live Leadership Updates

    See more
    • Rafael Holdings and Cyclo Therapeutics Enter into a Definitive Merger Agreement

      Cyclo Therapeutics' TransportNPC™ Phase 3 clinical trial for Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C1, a rare and fatal genetic disease, is fully enrolled and results from the 48-week interim analysis are expected in the middle of 2025 NEWARK, N.J. and GAINESVILLE, Fla., Aug. 22, 2024 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE:RFL), and Cyclo Therapeutics, Inc. (NASDAQ:CYTH) today announced that they have entered into a definitive merger agreement to combine the two companies to focus on the development of Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C1. On consummation of the merger, Rafael Holdings will issue shares of its Class B common

      8/22/24 6:50:00 AM ET
      $CYTH
      $RFL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Real Estate
      Finance
    • Rafael Holdings and Cyclo Therapeutics Enter Into a Definitive Merger Agreement

      Cyclo Therapeutics' TransportNPC™ Phase 3 clinical trial for Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C1, a rare and fatal genetic disease, is fully enrolled and results from the 48-week interim analysis are expected in the middle of 2025 Rafael Holdings, Inc. (NYSE:RFL), and Cyclo Therapeutics, Inc. (NASDAQ:CYTH) today announced that they have entered into a definitive merger agreement to combine the two companies to focus on the development of Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C1. On consummation of the merger, Rafael Holdings will issue shares of its Class B common stock to Cyclo Therapeutics' shareholders, based on an exchange ratio

      8/22/24 6:50:00 AM ET
      $CYTH
      $RFL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Real Estate
      Finance
    • Cornerstone Pharmaceuticals Strengthens Scientific Advisory Board with the Appointment of Distinguished Scholar Jason Locasale, Ph.D.

      CRANBURY, N.J., July 06, 2022 (GLOBE NEWSWIRE) -- Cornerstone Pharmaceuticals, Inc. ("Cornerstone" or the "Company"), a company focused on rare cancer therapeutics and formerly known as Rafael Pharmaceuticals, today announced the appointment of Jason Locasale, Ph.D., as a member of the Company's Scientific Advisory Board. Dr. Locasale is a highly respected scholar and brings to Cornerstone deep expertise in cancer metabolism, metabolomics, nutrition and the metabolic interface of epigenetics. "Dr. Locasale is an internationally recognized leader in the use of metabolomics approaches to study cancer biology and metabolism," said Sanjeev Luther, President & CEO at Cornerstone Pharmaceutical

      7/6/22 8:00:00 AM ET
      $RFL
      Real Estate
      Finance

    $RFL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Exec Chairman, CEO & President Jonas Howard S bought $16,742,985 worth of Class B Common Stock (13,080,457 units at $1.28) (SEC Form 4)

      4 - Rafael Holdings, Inc. (0001713863) (Issuer)

      6/9/25 5:19:19 PM ET
      $RFL
      Real Estate
      Finance
    • Chief Financial Officer Polinsky David exercised 76,882 in-the-money units of Class B Common Stock at a strike of $1.28, increasing direct ownership by 40% to 270,422 units (SEC Form 4)

      4 - Rafael Holdings, Inc. (0001713863) (Issuer)

      5/30/25 1:56:44 PM ET
      $RFL
      Real Estate
      Finance
    • Director Sieger Markus exercised 35,000 in-the-money units of Class B Common Stock at a strike of $1.28, increasing direct ownership by 23% to 190,182 units (SEC Form 4)

      4 - Rafael Holdings, Inc. (0001713863) (Issuer)

      5/29/25 3:04:58 PM ET
      $RFL
      Real Estate
      Finance

    $RFL
    Financials

    Live finance-specific insights

    See more
    • Rafael Holdings Provides Update on Rafael Pharmaceuticals' Two Phase 3 Trials of CPI-613® (Devimistat), AVENGER 500 in Metastatic Pancreatic Cancer and ARMADA 2000 in Relapsed or Refractory Acute Myeloid Leukemia

      Phase 3 Clinical Trial in Metastatic Pancreatic Cancer Did Not Meet its Primary Endpoint of Improved Overall Survival Independent Data Monitoring Committee Recommended the Phase 3 Clinical Trial in Relapsed or Refractory Acute Myeloid Leukemia Be Stopped Due to Lack of Efficacy Rafael Holdings to Host Conference Call Today at 8:00 a.m. ET NEWARK, N.J., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc., (NYSE:RFL), a holding company focused on developing novel cancer metabolism therapeutics through its Barer Institute, investment in Rafael Pharmaceuticals, Inc. ("Rafael Pharmaceuticals") as well as other investments in early-stage ventures, today announced that the AVENGER 500 Phas

      10/28/21 7:00:00 AM ET
      $RFL
      Real Estate
      Finance

    $RFL
    SEC Filings

    See more
    • SEC Form 10-Q filed by Rafael Holdings Inc.

      10-Q - Rafael Holdings, Inc. (0001713863) (Filer)

      6/11/25 7:53:42 AM ET
      $RFL
      Real Estate
      Finance
    • Rafael Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Rafael Holdings, Inc. (0001713863) (Filer)

      6/11/25 7:19:07 AM ET
      $RFL
      Real Estate
      Finance
    • Amendment: SEC Form SCHEDULE 13D/A filed by Rafael Holdings Inc.

      SCHEDULE 13D/A - Rafael Holdings, Inc. (0001713863) (Subject)

      6/9/25 5:22:02 PM ET
      $RFL
      Real Estate
      Finance

    $RFL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by Rafael Holdings Inc.

      SC 13D/A - Rafael Holdings, Inc. (0001713863) (Subject)

      9/30/24 5:40:03 PM ET
      $RFL
      Real Estate
      Finance
    • Amendment: SEC Form SC 13D/A filed by Rafael Holdings Inc.

      SC 13D/A - Rafael Holdings, Inc. (0001713863) (Subject)

      6/18/24 6:12:11 PM ET
      $RFL
      Real Estate
      Finance
    • SEC Form SC 13D/A filed by Rafael Holdings Inc. (Amendment)

      SC 13D/A - Rafael Holdings, Inc. (0001713863) (Filed by)

      10/24/23 4:43:18 PM ET
      $RFL
      Real Estate
      Finance